日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer

肿瘤突变负荷对早期非小细胞肺癌新辅助和辅助免疫检查点抑制剂治疗的临床价值

C F Quintanilha, Julia; Li, Gerald; Graf, Ryon P; Gasco, Amaya; Mitchell, Jerry; Huang, Richard S P

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

微卫星不稳定性及肿瘤突变负荷在预测转移性去势抵抗性前列腺癌免疫检查点抑制剂疗效方面的临床应用价值

Sayegh, Nicolas; Graf, Ryon P; Swami, Umang; Ozay, Zeynep Irem; Hage Chehade, Chadi; Elvin, Julia A; Lin, Douglas; Quintanilha, Julia C F; Li, Gerald; Bryce, Alan H; McKay, Rana R; Ross, Jeffrey S; Zhang, Tian; Agarwal, Neeraj

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications

PARP抑制剂治疗前前列腺癌中BRCA逆转突变的出现:临床和治疗意义

Lin, Douglas I; Lawrence, Elizabeth; Danziger, Natalie; Ye, Huihui; Decker, Brennan; Gjoerup, Ole; Graf, Ryon P; Ross, Jeffrey S; Huang, Richard S P; Elvin, Julia A; Mata, Douglas A; McKay, Rana R

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

在超过 8000 名涵盖 24 种癌症类型的患者中,肿瘤突变负荷与免疫检查点抑制剂治疗后的生存率之间的关系

Gandara, David R; Agarwal, Neeraj; Gupta, Shilpa; Klempner, Samuel J; Andrews, Miles C; Mahipal, Amit; Subbiah, Vivek; Eskander, Ramez N; Carbone, David P; Riess, Jonathan W; Sammons, Sarah; Snider, Jeremy; Bouzit, Lilia; Cho-Phan, Cheryl; Price, Megan; Li, Gerald; Quintanilha, Julia C F; Huang, Richard Sheng Poe; Ross, Jeffrey S; Fabrizio, David; Oxnard, Geoffrey R; Graf, Ryon P

Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types"

作者对“致编辑的信”的回应:“超过8000名24种癌症患者接受免疫检查点抑制剂治疗后的肿瘤突变负荷和生存率”

Graf, Ryon P; Gandara, David R

Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

更正:真实世界实践中基于BRCA1/2和瘢痕组织HRD特征的卵巢癌患者接受PARP抑制剂维持治疗的有效性

Richardson, Debra L; Quintanilha, Julia C F; Danziger, Natalie; Li, Gerald; Sokol, Ethan; Schrock, Alexa B; Ebot, Ericka; Bhardwaj, Neeru; Norris, Tanesha; Afghahi, Anosheh; Frachioni, Anthony; Washington, Christina; Dockery, Lauren; Elvin, Julia; Graf, Ryon P; Moore, Kathleen N

Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

同源重组修复改变与转移性激素敏感性前列腺癌患者预后的相关性

Hage Chehade, Chadi; Graf, Ryon P; Ozay, Zeynep Irem; Gebrael, Georges; Sayegh, Nicolas; Li, Gerald; Maughan, Benjamin L; Antonarakis, Emmanuel S; McKay, Rana R; Agarwal, Neeraj; Swami, Umang

LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial

LRP1b缺失可预测非小细胞肺癌患者对免疫疗法的敏感性:一项基于III期CheckMate-026随机试验的分析

Armstrong, Andrew J; Dietz, Hilary; Balli, David; Geese, William J; Duan, Chunzhe; Hung, Yu-Han; Ip, Virginia; Li, Gerald; Graf, Ryon P; Ready, Neal

Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer

在晚期非小细胞肺癌患者的全面基因组分析中,伴随诊断生物标志物结果低于检测限的临床应用价值

Li, Gerald; Greene, Stephanie B; Kaur, Baljinder; Keller-Evans, Rachel B; Graf, Ryon P; Decker, Brennan; Smith, David L; Huang, Richard S P

FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity

FoundationOne CDx 和 FoundationOne Heme 能以高灵敏度和特异性检测 Epstein-Barr 病毒

Honecker, Julius; Paffenholz, Dirk; Jungmann, Julian; Wieland, Thomas; Kou, Angela A; Yang, Soo-Ryum; Vanderbilt, Chad M; Shanmugam, Vignesh; Montesion, Meagan; Graf, Ryon P; Albacker, Lee A; Lin, Douglas I; Heilmann, Andreas; Lakis, Sotirios; Hickman, Richard A; Decker, Brennan; Robertson, Alex; Ritterhouse, Lauren L; Mata, Douglas A